简介:摘要:目的:研究枸地氯雷他定片联合他克莫司软膏治疗特应性皮炎的疗效以及对免疫因子水平的影响。方法:在特应性皮炎患者中选出92例,根据随机数字表法分成对照组(枸地氯雷他定片治疗)和观察组(对照组的用药基础上给予他克莫司软膏治疗),对比两组的总有效率、SCORAD评分、免疫因子水平等。结果:观察组的总有效率较对照组高,且SCORAD评分低于对照组,P<0.05;观察组治疗后的血清IL-2和IFN-γ水平均高于对照组,血清IL-4和IL-31水平均低于对照组,P<0.05。结论:枸地氯雷他定片联合他克莫司软膏治疗特应性皮炎疗效肯定,有助于促进患者临床症状体征的缓解,并调节免疫因子平衡。
简介:摘要:目的:探究三七人参汤联合洛赛克治疗胃出血的临床效果分析及对患者胃功能的影响。方法:选取2018年7月至2019年6月120例需尽早治疗的胃出血的患者作为研究对象,将其随机分为试验组和对照组,每组60例。对照组给予洛赛克治疗,试验组则在对照组基础上给予三七人参汤治疗。对比两组临床疗效及治疗前后凝血功能指标凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、D-二聚体(D-D)、纤维蛋白原(FIB)。结果:试验组止血有效率为100%明显高于对照组76.67%,比较差异有统计学意义(P<0.05);治疗14天后各组凝血功能及D-D、PLT水平较治疗前提升,且试验组明显高于对照组,差异均有统计学意义(P<0.05)。结论:三七人参汤联合洛赛克可有效改善胃出血及胃凝血功能,止血疗效确切。
简介:【摘要】目的:研究与观察门冬胰岛素联合地特胰岛素治疗围手术期糖尿病的疗效及安全性。方法:选取我院收治的围手术期糖尿病患者 50例为对象进行研究,将其随机分为对照组和观察组,各 25例。对照组于三餐前采用门冬胰岛素行皮下注射,观察组于三餐前采用门冬胰岛素联合睡前地特胰岛素行皮下注射。观察比较两组血糖达标时间、胰岛素用量以及低血糖发生率。结果:观察组血糖达标时间较对照组显著较短,而胰岛素用量较对照组显著较少,低血糖发生率低,且组间差异对比 P<0.05。结论:门冬胰岛素联合地特胰岛素对围手术期糖尿病治疗的效果非常显著,即可快速有效控制患者血糖水平,还能减少胰岛素用量,降低低血糖发生率,安全性高,值得应用推广。
简介: 【摘要】 目的:倍他乐克联合可达龙、门冬氨酸钾镁治疗急性心肌梗死并发恶性心律失常的临床疗效及安全性。方法:选取 2018年 8月 -2019年 8月笔者所在医院收治的 78例急性心肌梗死并发恶性心律失常患者作为研究对象,随机分为两组,均给予常规支持治疗,对照组单用倍他乐克治疗,研究组在对照组基础上联合可达龙、门冬氨酸钾镁用药,比较两组治疗前后心律失常恢复情况及临床效果。结果:两组治疗前心室率比较差异无统计学意义( P>0.05),治疗后 24 h两组心室率均低于治疗前,且研究组低于对照组,差异均有统计学意义( P<0.05);研究组总有效率明显高于对照组,差异有统计学意义( P<0.05);研究组心源性事件发生率低于对照组,差异有统计学意义( P<0.05),两组死亡率比较差异无统计学意义( P>0.05)。结论:倍他乐克、可达龙、门冬氨酸钾镁三药联合治疗急性心肌梗死并发恶性心律失常疗效确切,能明显抑制心律失常,促进转复,且并发症少,建议临床推广应用。 【关键词】 倍他乐克; 可达龙; 门冬氨酸钾镁; 急性心肌梗死; 急性心律失常; 效果 [Abstract] Objective: To evaluate the efficacy and safety of Betaloc combined with Dacron and potassium magnesium aspartate in the treatment of acute myocardial infarction complicated with malignant arrhythmia. Methods: from August 2018 to August 2019, 78 patients with acute myocardial infarction complicated with malignant arrhythmia in our hospital were randomly divided into two groups, which were given routine support treatment. The control group was treated with betaloc alone, and the study group was treated with Dalong and potassium magnesium aspartate on the basis of the control group to compare the recovery of arrhythmia before and after treatment And clinical effect. Results: there was no significant difference between the two groups before treatment (P > 0.05). 24 hours after treatment, the ventricular rate of the two groups was lower than that before treatment, and the difference between the study group and the control group was statistically significant (P < 0.05); the total effective rate of the study group was significantly higher than that of the control group, and the difference was statistically significant (P < 0.05); the incidence of cardiogenic events in the study group was lower than that of the control group, and the difference was statistically significant (P < 0.05) There was no significant difference in mortality between the two groups (P > 0.05). Conclusion: the combination of Betaloc, Dalong and potassium magnesium aspartate is effective in the treatment of acute myocardial infarction complicated with malignant arrhythmia. It can obviously inhibit arrhythmia, promote recovery, and has few complications. It is recommended to be widely used in clinical practice.